Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells.

Abstract: An ultrasound cardiac stimulation system includes: a system for measuring the heart electrical activity; a system for generating a beam of focussed ultrasound signals focussed on a targeted zone, the signals being calibrated to generate electrical stimulation in a zone of the heart, the beam generation being synchronised with a first selected time of the electrocardiogram, the generation of the beam corresponding to a pulse with a duration of less than 80 ms; a system for locating the targeted zone coupled with a system for positioning the system for generating the focussed beam to control the beam of focussed ultrasound signals in the targeted zone, the location system being synchronised with the system for generating the beam of focussed signals; a single monitoring system following in real time a temperature and tissue deformation in the targeted zone, the monitoring system taking measurements in synchronisation with the rhythm of the electrocardiogram.

Abstract: Some embodiments are directed to a method for preparing a skin substitute, a dermal substitute, to a skin substitute, to a dermal substitute and to a kit for implementing the method. Some other embodiments are directed to a graft that can consist of of a skin substitute and to the use thereof as treating a skin disorder and/or a loss of skin substance.

Abstract: A system for ablating or monitoring a zone of the heart, includes a system to measure the heart electrical activity; a phased array for generating a beam of focussed ultrasound signals on a targeted zone of the heart; an imaging system determining an image of a transcostal wall projected in an image plane of the phased array by taking into consideration a position and direction of the phased array and making it possible to deactivate elements of the phased array in accordance with the position of the elements with regard to the position of the projected image of the transcostal wall; a positioning system to control the position of a focussed zone of a beam of focussed ultrasound signals on the targeted zone, a monitoring system to measure a temperature and tissue deformation in the targeted zone; and a device for measuring a level of cavitation in the targeted zone.

Abstract: The invention concerns a biocompatible oily ferrofluid comprising iron-oxide based magnetic nanoparticles and an oil phase comprising at least one fatty acid ester, characterized in that said magnetic nanoparticles are surface functionalized by molecules of one or more phospholipids, and in particular a biocompatible oily ferrofluid comprising iron-oxide based magnetic nanoparticles and an oil phase comprising at least one fatty acid ester, said iron-oxide based magnetic nanoparticles forming a colloidal dispersion in said oil phase from a temperature belonging to the range from 20 to 80° C.

Abstract: A method of segmentation of a three-dimensional image for generating a model of a myocardial wall includes recording a three-dimensional image of a wall of the myocardium, the wall delimiting at least one cavity of the heart; segmenting a continuous part of the wall into at least a first volume having a thickness less than a first predefined thickness threshold of between 0 and 5 mm and a second volume of a continuous part of the wall having a thickness greater than the first threshold; generating a model of the wall of the myocardium, where the continuous part of the wall of the myocardium is modelled according to at least two volumes that continue each other.

Abstract: The present invention relates to desmethylanethole trithione (AOX) and derivatives thereof, especially derivatives of formula (I), for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin,

Abstract: An MRI method is disclosed for the geometrical characterisation of pulmonary airways on the basis of a first tridimensional image of at least one bronchus of a bronchial tree and includes: acquiring a first MRI image, an MRI sequence being synchronised with a respiratory frequency; filtering the first image; segmenting a portion of the filtered image including the contours of the bronchial tree and its inner volumetric portion; estimating at least one plane of cut of a bronchus; generating at least one image slice of a bronchus; estimating, for each image slice, an area contained within the bronchial wall and/or a bronchial wall thickness.

Abstract: A device for generating a pivot drug database implemented in a computer system, the device includes an extraction unit configured for extracting the data from a set of elementary drug data sources, the elementary drug data sources storing drug-related data, each elementary data source being associated with a representation of the data; a structuring unit configured for structuring the extracted data by applying a pivot ontology to the extracted data, the pivot ontology defining classes derived from one or more ontologies of the drug and relationships between the classes, which provides structured data associated with a graph representing the relationships between the classes corresponding to the structured data; the device being configured for generating the pivot drug database according to the graph and the structured data, the pivot database storing the structured data. Applications: drug interaction analysis tools, tool for assisting medical prescription.

Abstract: The invention relates to a system (10) for the intraosseous injection of surgical cement comprising an external sleeve (11); a cannula (13) mounted coaxially in the external sleeve, said cannula being able to be moved along a longitudinal axis (A) in the external sleeve, the cannula being provided with a tapered distal point (15); and a stent (18) accommodated in the interior of the external sleeve, said stent being mounted around a distal end (16) of the cannula. The invention also relates to a kit comprising a system of this type for the injection of surgical cement, surgical cement injection means capable of being connected to the proximal end of the internal cannula, and possibly surgical cement.

Abstract: A medical device includes a catheter, which includes a first lumen for injection of a first volume of a treatment solution, the first lumen opening out at the distal end of the catheter; and a junction element extending the first lumen at the end of the catheter including a diameter at the distal end thereof less than the diameter of the catheter.

Abstract: The invention relates to a method for determining active concentrations of an analyte and optionally kinetic constants for the interaction of the analyte with a ligand in complex biological samples by means of surface plasmon resonance comprising the use of an auto-blank.

Abstract: The present invention relates to desmethylanethole trithione (AOX) and derivatives thereof, especially derivatives of formula (I), for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin,

Abstract: The invention relates to the field of therapy, in particular dermatology. Inventors herein identify for the first time inhibitors of matrix metalloproteinase-9 (MMP9) as active molecules for use for preventing, treating or alleviating skin depigmenting disorders in a subject in need thereof, and describe compositions and kits comprising such inhibitors as well as uses thereof. Inventors further describe a method for screening pharmaceutically active molecules suitable for preventing, treating or alleviating a depigmenting disorder as well as methods for evaluating the efficacy of a depigmenting disorder treatment involving an inhibitor of MMP9 or for monitoring the course of depigmenting disorder in a subject exposed to such a treatment.

Abstract: The invention relates to a self-expanding intraosseous stent (100) intended to contain intraosseous cement, characterized in that the stent comprises a central part (101) and two lateral parts (102, 103) arranged on either side of the central part and extending along the same longitudinal axis (X), and in that the central part has a radial force lower than the radial force of the lateral parts.

Abstract: The invention relates to a self-expanding intraosseous stent (100) intended to contain intraosseous cement, characterized in that the stent comprises a central part (101) and two lateral parts (102, 103) arranged on either side of the central part and extending along the same longitudinal axis (X), and in that the central part has a radial force lower than the radial force of the lateral parts.

Abstract: A method for quantifying the presence of fats in a region of the heart includes an acquisition of an image of at least one cavity of the heart and of a wall; a selection of at least one pixel of a section through the heart including a density of pixels included in a first range of values; a growth in the selection of at least one pixel so as to define an extended 3D zone delimited by the cavity; an operation of homogeneous dilation of the extended 3D zone making it possible to define a dilated volume; an operation of extracting a peripheral region arising from the subtraction between the dilated volume and the extended 3D zone; a quantification of the number of pixels of a second range of values within the peripheral region.

Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

Abstract: The system for intubation comprises:—a disposable sterile endotracheal tube (30) having proximal (30P) and distal (30D) end. It is essentially characterized with:—a disposable removable sterile optical fiber bundle (20) having a proximal (20P) and a distal (20D) end, to be inserted into the airway lumen 30P (32) of said endotracheal tube (30), so that said distal end (20D) is capable of illuminating a region of said distal end (30D), and of collecting an image of said illuminated region, and—a module (10) comprising a screen (11) and a light source (12), to be connected to said optical fiber bundle (20) to provide light to the distal end (20D) of said optical fiber bundle (20), and to display on the screen (11) said image collected from the distal end (20D) of said optical fiber bundle (20).